Monitor for additional insider sales in the next 30 days; while this cluster is within normal range for a company of this size, repeated selling by C-suite executives could signal waning confidence. Compare to historical patterns and upcoming earnings timing.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $482.92entry
- T+1 · 9mo ago −0.58%α −0.03% · $480.12
- T+5 · 9mo ago −1.32%α −0.22% · $476.54
- T+20 · 8mo ago −5.79%α −0.55% · $454.96
- T+60 · 6mo ago −10.87%α −17.82% · $430.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Vertex Pharmaceuticals EVPs, the Chief Commercial Officer and Chief Legal Officer, sold shares in open-market transactions totaling approximately $1.6 million over the past week. These were opportunistic sales of existing holdings, not tied to a specific corporate event.
Key Financial Metrics
Key Facts
- EVP and Chief Commercial Officer Duncan McKechnie sold 2,437 shares for $1,158,306.10 at $475.30 per share on March 4, 2026.
- EVP and Chief Legal Officer Joy Liu sold 892 shares for $442,396.32 at $495.96 per share on March 2, 2026.
- Total value of the insider trading cluster: $1,600,702.42 in open-market sales.
- Both transactions were reported on Form 4 as open-market sales (code 'S'), indicating deliberate dispositions.
- Sales represent approximately 0.0014% of Vertex's $117.1B market cap, well below the 0.1% threshold for materiality.
Financial Impact
$1.6 million in total insider sales, or 0.0014% of market capitalization
Risk Factors
- Perception risk if selling continues ahead of earnings or a product decision.
- Concentration risk in executive ownership if such sales become a trend.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-VRTX-1772831202282 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers